Mountain Valley MD Holdings Inc., through its subsidiary, Mountain Valley MD Inc., operates as a health and wellness company. The company engages in the implementation and licensing of its technologies to pharmaceutical, vaccine, and nutraceutical third parties. It offers Quicksome oral drug formulation and delivery technologies; Quicksol solubility formulation technology; and dose sparing adjuvant. In addition, the company is developing IM032 for the treatment of male beagle dogs for comparing intramuscular and subcutaneous dosing. Mountain Valley MD Holdings Inc. is headquartered in Concord, Canada.